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Context: Existing biochemical tests for polycystic ovary syndrome (PCOS) have poor sensitivity and
specificity. Many women with PCOS have high anti-Müllerian hormone (AMH) concentrations;
thus, this may be a useful addition to the diagnostic criteria.
Objective:A systematic literature reviewwas performed to assess the true accuracy of AMH in the
prediction of PCOS and to determine the optimal diagnostic threshold.
Data Sources: Published and gray literature were searched for all years until January 2013.
StudySelection:ObservationalstudiesdefiningPCOSaccordingtotheRotterdamcriteriaandassessing
the value of AMH in diagnosing PCOSwere selected. Ten studies of the initial 314 hits reporting AMH
values inthediagnosisofPCOSwere includedinthemeta-analysisandtheconstructionofthesummary
receiver-operating characteristic curve. Four studies that plotted individual AMH serum levels of
women with PCOS and controls on graphs were selected for individual data extraction.
Data Extraction: Two researchers independently assessed the abstracts resulted from the initial
search against the inclusion criteria, graded the papers for selection and verification biases, and
selected the papers that assessed the value of AMH in diagnosing PCOS. Datawere extracted from
4 studies with the plotted individual data on graphs with the help of computer software.
Data Synthesis: Themeta-analysis of the extracted data demonstrated the specificity and sensitivity
indiagnosingPCOS in the symptomaticwomenof79.4%and82.8%, respectively, for a cutoff value of
AMHof4.7ng/mL.Theareaunder thecurvewas0.87 (95%confidence interval0.83–0.92), identical
with the area under the curve of 0.87 for the summary receiver-operating characteristic curve
involving 10 separate studies.
Conclusions: AMH may be a useful initial diagnostic test for PCOS subject to validation in pro-
spective population cohorts. (J Clin Endocrinol Metab 98: 3332–3340, 2013)
Polycystic ovary syndrome (PCOS) is themost commonendocrinedisorder inwomenof reproductive ageand
the most frequent cause of hyperandrogenism and oligo-
anovulation, both of which have substantial psychologi-
cal, social, and economic consequences (1). An increased
awareness of this disorder in the general population and
medical communities has taken place in recent years, with
greater understanding of the long-term associations of the
condition, including the metabolic syndrome and its as-
sociated comorbidities (2), as well as the risk of specific
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diseases such as endometrial cancer and insulin-resistant
diabetes in women with a history of PCOS (3–5). Because
of theheterogeneity in its presentation,womenwithPCOS
frequently present to a range of disciplines including pri-
mary care, endocrinology, and gynecology. Although
there has been considerable debate regarding the preferred
diagnostic criteria for this heterogeneous condition,
within Europe the 2003 Rotterdam criteria have gained
considerable ground across specialties (6). This requires
the presence of 2 or more of the following: chronic
anovulation, clinical or biochemical signs of hyperandro-
genism, and polycystic ovaries on transvaginal ultra-
sonography. The accurate assessment of hyperandrogen-
emia in women can be technically challenging with the
immunoassays in widespread use, and although the free
androgen index is often also used, its validity is uncertain
(7–9). Thus, an accurate single diagnostic biochemical test
would have advantages.
Anti-Müllerian hormone (AMH) is produced by the
granulosa cells of follicles from the time at which follicle
growth is initiated (10, 11) and is a regulator of early
follicular recruitment from the primordial pool (12).
AMH expression continues until follicles reach approxi-
mately 8 mm in diameter, and expression is very low in
larger antral follicles (13, 14). Consequently, there is a
good correlation between AMH and antral follicle count
(AFC) (15–20). Women with PCOS have high AMH con-
centrations (21, 22), and accordingly, AMHhas been pro-
posed as a marker of PCOS and as a substitute for AFC in
the diagnosis of PCOS (21, 23–26). AMH also correlates
with the other criteria of PCOS: oligoamenorrhea and hy-
perandrogenism (17, 18, 20, 26–28). At present a variety
of cutoff values of AMH have been proposed but with
varying sensitivity and specificity, and the optimal thresh-
old is unknown (23–25, 29). Whether these thresholds
should be age specific is also unclear, given the marked
changes in AMH in the normal population across the re-
productive life span (30) and the possibility that AMH
declines in a less rapid manner in women with World
Health Organization class II anovulatory infertility (31).
The aim of the present systematic literature reviewwas
to assess the accuracy of AMH in the prediction of PCOS
and to perform a data aggregation meta-analysis to deter-
mine the optimal diagnostic threshold.
Materials and Methods
Search strategy
The following electronic databases were searched up to
January 2013: PubMed, Embase, Medline, Web of Knowledge,
and the Cochrane trial register. Search terms for PCOS (MeSH,
PCOS, PCOD, hyperandrogenism, hirsutism) and antimüllerian
hormone, müllerian-inhibiting substance, or müllerian-inhibit-
ing factor were used. A period including all years through Jan-
uary 2013 was covered by the search. The search was limited to
papers published inEnglish and related tohumans.The abstracts
of all studies identified were graded by 2 researchers (S.I. and
S.M.N.). Any article that could possibly be of value for the as-
sociation between AMH and the PCOS was preselected. For
completeness we also identified studies that assessed the diag-
nostic value of AMH for PCOS according to National Institute
ofHealth (NIH) orAndrogen Excess Society (AES) criteria (Sup-
plemental Table 1, published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org). Only pa-
pers defining PCOS according to the Rotterdam criteria were
included in our primary analysis to prevent large heterogeneity
by pooling studies defining PCOS based on different criteria. In
the next step, 2 researchers (S.I. and T.W.K.) carefully read and
judged all preselected articles independently. If it was judged
possible to construct 2  2 tables, in which the test result at a
certain cutoffwas related to theoutcomeparameter of PCOS, the
study was selected for final recordings and analysis. In the event
of any disagreement between the 2 researchers, the opinion of a
third researcher (S.M.N.) was final. In every selected study, the
reference list was scanned to identify studies that could possibly
be included in the selection and then processed as described.
Each selected study was further scored by the researchers S.I.
and T.W.K. on the following study quality characteristics: 1)
sampling (consecutive vs other); 2) data collection (prospective
vs retrospective); 3) study design (cohort vs case-control study);
4) blinding (present or absent); 5) selection bias; and 6) verifi-
cation bias. Also, data on the cutoff levels usedwere recorded, as
was the assay used for AMH measurement.
Because this review used only published data from the liter-
ature, no approval from an institutional review board was
required.
AMH assay
Serum AMH values were standardized to give AMH mea-
surements in nanograms per milliliter using the following con-
version formula: 1 ng/ml 7.143 pmol/L. The included studies
either reported AMH according to the Immunotech-Beckman
Coulter assay (Immunotech-Beckman Coulter, Marseille, France)
or the DSL assay (Diagnostic Systems Laboratories Inc, Webster,
Texas)as reported inTable1.Weconverted theDiagnosticSystems
Laboratories assaydata into Immunotech-BeckmanCoulter values
using the conversion formula, 2.02 * Diagnostic Systems Labora-
tories Immunotech-BeckmanCoulter,which has a reported r2 of
0.85andhasbeenusedpreviously fordataaggregationstudies (32).
Analysis
The datawere reported graphically in 4 studies and extracted
using Plot Digitizer software (provided by sourceforge.net,
found online at http://plotdigitizer.sourceforge.net/) to convert
data points on the graphs into numerical data (33). Repeated
data points were isolated using nonparametric bootstrap sam-
pling (34) guided by the descriptive statistics provided in the
supporting text, andwerepeatedly sampled thepossible repeated
data points until we found the set that matched the descriptive
statistics. Initial regression tree analysis (35) of the resulting data
set showed that age did not contribute as a factor in an optimal
predictive model of PCOS given both age and AMH. We there-
fore restricted full analysis to AMH alone, performing an ag-
doi: 10.1210/jc.2013-1393 jcem.endojournals.org 3333
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 15 August 2014. at 03:45 For personal use only. No other uses without permission. . All rights reserved.
gregated data meta-analysis with generation of receiver-operat-
ing characteristic (ROC) curve for the diagnosis of PCOS.
The optimal sensitivity and specificity from the ROC curve
for the 4 combined studies was collatedwith the sensitivities and
specificities reported for the 10 studies resulted from the system-
atic search, forming a data set for summary ROC (SROC) anal-
ysis. Publication bias was assessed using the funnel plots of re-
ported sensitivities and specificities against study size, following
themethodology described byDelgado-Bolton et al (36). A sym-
metric plot would provide reassurance, whereas an asymmetric
plot would suggest the presence of publication bias.
Initial analysis of the combined diagnostic log-odds ratio
(OR) showed that the collected studies were heterogeneous with
respect toOR, indicating that studies should be assignedweights
inversely proportional to the variance of the log of the diagnostic
OR of the study (37). Subsequent analysis followed the standard
SROC methodology (38–40) of the fol-
lowing: 1) log-adjusting sensitivities and
specificities and separation intovariables
D (the diagnostic log-OR) and S (a mea-
sure of diagnostic threshold); 2) weight-
ing the D and S values by inverse vari-
ance; 3) fitting the adjusted data to the
affine model D  a  bS; P  NS 4)
reversing the log adjustment of a and b to
obtain a summary ROC curve.
Results
Systematic review
The systematic search of the bio-
medical databases produced 484
hits; after excluding duplicates, 314
citations were identified (Figure 1).
Unpublished literature (gray litera-
ture, opengrayweb site) fulfilling the
search indexes was not identified.
After excluding articles based on the
title or abstract, 55 articles were as-
sessed fully for eligibility. Ten stud-
ies reported the capacity of AMH in
diagnosing PCOS according to the
Rotterdam criteria (6) and were in-
cluded in the meta-analysis (22–25,
Figure 1. Flow chart of the systematic search methodology. n, number of studies; N, number of
study participants diagnosed with PCOS.
Table 1. Characteristics of the 10 Included Studies
Author Year Study
Diagnosis
of PCOS
N (PCOS) per
Rotterdam Age, y
Cutoff,
ng/mL Sensitivity Specificity
AUC,
95% CI
Selection
Bias
Verification
Bias Assay
Homburg et al (47) 2013 Prospective
case-control
Rotterdam 90 32.1  3.3 6.72 60.0 98.2 0.81 Yes No DSL
Woo et al (42) 2012 Prospective
cross-sectional
Rotterdam 87 22.0–38.0 7.82 75.9 86.8 0.868 No No IBC
0.801–0.919
Chao et al (45) 2012 Case-control Rotterdam 45 29.0–38.0 3.50 74.0 79.0 NA No No DSL
Eilertsen et al (25) 2012 Case-control Rotterdam
AES
56 33.3  5.5 2.80 94.6 97.1 0.992 Yes No DSL
0.986–0.999
Lin et al (29) 2011 Prospective
case-control
Rotterdam 126 27.7  5.8 7.30 76.0 70.0 0.774 Yes No DSL
0.720–0.829
Dewailly et al (24) 2011 Prospective Rotterdam 62 20.1–34.0 4.90 92.0 97.0 0.973 Yes No IBC
0.947–0.998
Li HWR et al (46) 2011 Retrospective Rotterdam 33 25.0–31.0 5.88 79.0 96.0 0.913 Yes No IBC
0.843–0.982
Li L et al (22) 2010 Cohort Rotterdam 47 17.0–25.0 8.00 61.7 70.0 0.664 Yes No DSL
0.551–0.778
Hart et al (43) 2010 Prospective
cohort
Rotterdam
NIH
64 14.5–17.6 4.20 53.1 69.8 0.64 No No IBC
0.55–0.72
Pigny et al (23) 2006 Prospective
cohort
Rotterdam 73 22.0–36.4 8.40 67.0 92.0 0.851 Yes No IBC
0.796–0.905
Abbreviations: IBC, assay from Immunotech-Beckman Coulter; DSL, assay from Diagnostic Systems Laboratories Inc. Diagnosis of PCOS was
determined by the Rotterdam criteria. Age values are reported as range or mean  SD.
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42–47). The characteristics of the included studies are
listed in Table 1. Most the studies were prospective, but
selection biases were apparent in most of the studies,
which recruited theparticipants fromgynecological or fer-
tility clinics. We also identified 4 studies defining PCOS
according toAESorNIHcriteria,which assessed the value
of AMH in diagnosing PCOS (Supplemental Table 1) (25,
43, 48, 49). However, we have not conducted a meta-
analysis on the studies defining PCOS according to non-
Rotterdam criteria because this was not our primary ob-
jective and may introduce significant selection bias.
In addition, 4 of the above-mentioned 55 studies in-
cluded individual serum AMH levels in female partici-
pants with PCOS (according to the Rotterdam criteria)
and controls plotted in graphs (26,
45, 50, 51).WomenwithPCOSwere
recruited from gynecology/infertility
clinics, ie, were symptomatic, rather
than from the general population.
The controls usedwere similar for all
4 studies and specified the following:
1) had regular menstrual cycles with
an interval of 21–35 days; 2) had no
medical history of hirsutism or se-
vere acne; 3) had no evidence of en-
docrine disease; 4) had no history of
ovarian abnormalities; 5) hadnohis-
tory of ovarian or uterine surgery;
and 6) had no history of taking
medicines that contained hormones
within the previous 2 months. In the
study of Chao et al (45), all controls
had at least one natural pregnancy
carried to term. The raw data were
extracted with the assistance of soft-
ware and were combined in a single
data set of serumAMHlevels for146
femaleswith PCOS (according to the
Rotterdam criteria) and 136 control
womenwithoutPCOS.For2of these
studies, AMHwas plotted relative to
age, and therefore, a third data set
with AMH and age was created for
110womenwithPCOSand103con-
trols (26, 45).
Accuracy of AMH in diagnosing
PCOS (Rotterdam criteria)
Sensitivities and specificities for
the diagnosis of PCOS calculated
from each study reporting on AMH
are summarized in Table 1. The sen-
sitivity varied between 64% and
99%. There was no evidence of pub-
licationbias in the studies used toob-
tain summary statistics (Figure 2),
The SROC curve obtained from all
studies has high area under the curve
(AUC) of 0.87 (Figure 3, top panel).
Figure 2. AMH in the diagnosis of PCOS. Top panel, The summary ROC curve (thick line),
reported sensitivity and specificity values of the 10 included studies (circles), and the sensitivity
and specificity values for the individual patient data aggregation meta-analysis (square). Bottom
panel, ROC curve, optimal cutoff value, and AUC for the individual patient data aggregation
meta-analysis.
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Meta-analysis of the extracted data for accuracy
of AMH in diagnosing PCOS (Rotterdam)
The extracted raw data were used for descriptive sta-
tistics. Women with PCOS had a similar age range to
womenwithout PCOS [29 years (15–44 years) vs 31 years
(12–44 years), mean (range)]. Serum AMH was almost
4-fold higher in women with PCOS
compared with non-PCOS women
[median (25th to 75th percentile),
8.71 ng/mL (5.29–14.09 ng/mL) vs
2.36 ng/mL (1.52–4.24 ng/mL)].
Specificity and sensitivity in diagnos-
ingPCOSinsymptomaticwomenbyus-
ingAMHwerecalculatedfromthe raw
data set andwere79.4%and82.8%,
respectively, for a cutoff value of
AMH of 4.7 ng/mL. The AUC was
high [0.87, 95% confidence interval
(CI) 0.83, 0.92] suggesting that
AMH is a good diagnostic test of
PCOS (Figure 2, bottom panel).
Adding age toAMHin the predictive
model did not change the cutoff
value of AMH: the optimal classifi-
cation tree using both AMH and age
had a single bifurcation at the AMH
value 4.7 ng/mL, with age not con-
tributing as a variable.
Clinical value
Onthebasis of the summaryROC
curve depicted in Figure 2A, a range
of threshold AMH values for the di-
agnosis of PCOS with their associ-
ated sensitivities and specificities
were calculated (Table 2).
Discussion
This systematic review, extracted
data meta-analysis, and summary
ROC summarize the currently avail-
able evidence concerning the accu-
racy of AMH in the diagnosis of
PCOS. It would appear that AMH
has good discriminatory capacity
in separating normal women and
women with PCOS as defined by the
Rotterdam criteria (6). Several pre-
vious studies have suggested diag-
nostic thresholds for AMH for
PCOS diagnosis (22–25, 42–47).
Our summary graphic demonstrates that these may have
potentially over- or underestimated the diagnostic perfor-
mance. This is likely to reflect the variability in study de-
sign including sample size, recruitment source, age of par-
ticipants, and control selection. The composition of PCOS
subclasses within each of these studies may also have dif-
Figure 3. Funnel plots for the assessment of publication bias. Both plots are symmetrical about
the average value, suggesting that smaller studies tend to report sensitivity and specificity similar
to those for larger studies.
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fered, andAMHconcentrations have been shown to differ
relative to which of the 3 components of the Rotterdam
consensus statement arepresent (52).Theappropriateness
of our suggested threshold for the generic consensus def-
initionof PCOScanbe confirmed inwell-phenotypedpro-
spective population cohorts.
The largest study (24) has provided very similar values
to that derived from our aggregated data meta-analysis of
4.7ng/mLorgreater (33.6pmol/L), suggesting abiological
plausibility for this value, even though it did not contrib-
ute to our data meta-analysis. However, this study (24)
clearly excluded from the control group women with
asymptomatic polycystic ovaries whomay have increased
AMHlevels, thereby accentuating anydifference,whereas
other studies may have included them in the controls re-
sulting in different diagnosing thresholds (53). The impact
of different control selection has also been identified by
Rosenfield et al (48), who suggested anAMHgreater than
6.2 ng/mL for a diagnosis of PCOS according to NIH
criteria but a much higher cutoff level of 10.7 ng/mL for
specificallydiscriminatingPCOSwomen fromasymptom-
atic women with polycystic ovary morphology.
Although the meta-analysis and summary ROC curve
have focused on diagnosing PCOS according to the Rot-
terdam criteria, AMH would appear to have a good dis-
criminatory value in diagnosing PCOS according to AES
or NIH criteria also, as shown by the high AUC of the
ROC analysis of each individual study identified (Supple-
mental Table 1). The only contradictory study is by Hart
et al (43), but the authors acknowledge that by defining
PCOS based on the AES criteria, the control group in-
cluded teenaged girls with irregular cycles, so the study is
likely to have included girls who would be otherwise di-
agnosed as PCOS according to the Rotterdam criteria.
Due to the heterogeneous nature of PCOS, it has been
argued that no single value would be capable of defining
the disease but rather that AMH can only replace poly-
cystic ovary morphology (24, 25). The correlation of
AMH and AFC is well known and strong, and further-
more, AMH correlates weakly but significantly with oli-
gomenorrheaandbiochemicalhyperandrogenism(17,18,
20, 26–28). However, that AMH correlates with all of
these key features of the PCOS diagnosis would suggest a
diagnostic thresholdofAMHmaybeachievable accepting
limitations of the sensitivity and specificity. In support of
this possibility, a recent analysis of a case-control cohort
suggested that 6.7 ng/mLwould have a sensitivity of 60%
and specificity of 98.2% for the diagnosis of PCOS (47).
AFC is currently a cornerstone of PCOS diagnosis ac-
cording to the Rotterdam criteria (55). However, the cur-
rent diagnostic threshold of 12 or more follicles per ovary
has been questioned (24, 56). This is primarily due to
technical advances in imaging, whereby identification of
more follicles leads to a major but artificial increase in the
prevalence of polycystic ovary morphology in normal
populations and in particular in younger women (57–59).
Although this has led to some suggesting that polycystic
ovary morphology has no pathological significance (58),
others have recommended increasing the diagnostic
threshold for AFC (24, 59). A higher threshold of 19 fol-
licles has reported sensitivity and specificity of 81% and
92%, respectively, for the diagnosis of PCOS (24), but
because this is based in part on the quality of the ultra-
sound technology rather than a true biological/medical
discrimination, there is a significant inherent artificiality
to the proposed cutoffs (18, 21, 24). Consistent with this
is the even more recent suggestion that this threshold
should be raised to 26 follicles (60). Because AMH is pro-
duced from these small antral follicles (13), the alternative
of measuring it as a stable product, which is not subject to
the same ongoing technical advances or operator depen-
dence, would be attractive (61).
In view of the biphasic effect of age on serum AMH
values (30, 62–64), someauthors have suggested adapting
different thresholds according to the patients’ age (25).
Thismaybeparticularly relevant inadolescents andyoung
adults, in whom AMH levels are rising (30) and when the
diagnosis is frequently made (65). However, in our data
set, agedidnothaveaneffecton the suggestedcutoffpoint.
Although there is a need for analysis with larger data sets
with age groups younger than 25 years, we therefore at
Table 2. Sensitivity and Specificity of AMH-based PCOS Diagnosis
AMH Cutoff,
ng/mL
Specificity Sensitivity
Low
95% CI
Median
95% CI
High
95% CI
Low
95% CI
Median
95% CI
High
95% CI
2 31.6 39.7 47.8 89.0 93.2 97.3
3 50.7 59.6 67.7 87.0 91.8 96.6
4 65.4 73.5 80.1 80.1 85.6 91.1
4.7 72.1 79.4 86.0 76.7 82.9 89.0
5 75.0 81.6 88.2 72.6 79.5 85.6
6 83.1 89.0 94.1 61.6 69.2 76.7
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present suggest that age-specific thresholds with their in-
herent inconvenience are not required.
Limitations
Although the process of systematic literature review
and meta-analysis is a practical way of generating a more
powerful estimate of true-effect size with less random er-
ror than individual studies, it does come with some limi-
tations. First of all, the heterogeneity of the studiesmust be
addressed because it may affect the justification for pool-
ing the data into one analysis. In the case of the present
meta-analysis, heterogeneity was caused by both study
quality characteristics and slight differences in study pop-
ulations. This was overcome by using a growth curvewith
minimization of the residuals to develop an average/sum-
mary ROC curve. Additionally, the definition of included
studies was limited to those that defined PCOS according
to theRotterdamcriteria (6).However,we appreciate that
the derived value and its associated sensitivity and speci-
ficity may not be applicable for all PCOS subgroups and
confirmation of the optimal threshold for the various
PCOS subtypes is warranted.
Many of these methodological problems can be over-
come by using individual patient datameta-analysis, or as
shown here, using data aggregation approaches, which,
although not allowing adjustment for confounders, does
provide a large number of values for primary analysis.
Recent initiatives in this field include assessment of AMH
for the prediction of excessive ovarian response (66). We
acknowledge that we included only a fraction of the cu-
mulative data for the estimation of the AMH threshold
value, but the ROC resulted from the extracted data was
very similar to the summary ROC resulted from the entire
data. Thus, the expected variation in the suggested thresh-
old value is likely very small.
Most of the pooled studies assessedwomenwith PCOS
who were recruited from fertility clinics. This may have
underestimated or overestimated the sensitivity and spec-
ificity of AMH as a diagnostic test of PCOS due to the
potential differential PCOS case mix seen in that clinical
context. Case control studies classically overestimate the
performance characteristics of a diagnostic test; however,
potentially this effect of selection bias due to recruitment
froma fertility clinicmaybe small because there is no trend
of decreased sensitivity or specificity in the studies that
involved participants from the general population (Table
1).However,womenwith elevatedAMHdue toother rare
causes like granulosa cell tumors were clearly not in-
cluded. Future prospective population cohortswill be able
to confirm the utility and performance characteristics of
our suggested thresholds for the diagnosis of PCOS in the
general population.
Lastly, there are some limitations that apply specifically
to the method used to assess AMH levels. The studies in
thismeta-analysis did not use the sameAMHassay. There
is a noteworthy difference between the Beckman-Coulter
ELISA and the Diagnostic Systems Laboratories ELISA
leading to a wide dispersion of values (41, 44). In the
current study we have used a previously validated conver-
sion factor to align these assays to the Immunotech stan-
dards that now underlie the Beckman Coulter Generation
II assay (30, 33). This approach has been used previously
to derive a normal range of AMH across the life course,
with values equivalent to those observed in prospective
cohorts (30, 53, 54). However, the proposed threshold
value may change according to the AMH assay technique
until the development of an international standard.
Summary
The current systematic review and meta-analysis sug-
gest that AMH is a useful first-line investigation in the
identification of womenwith PCOS. Future assessment of
the role of AMH in the diagnosis of the various subcate-
gories of PCOS that inevitably exist with the current clas-
sification system is required.
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